Baur Frank Tobias

EVP Frank Tobias Baur bought 700 DBD shares at $46.12; prior DBD buys showed 66.67% 90-day win rate but stock unprofitable

Frank Tobias Baur, EVP of Operational Excellence, purchased 700 shares of DIEBOLD NIXDORF at $46.12 on 2025-05-09, increasing his stake to 38.6K shares (+1.8%). His prior trades at DBD show a mixed pattern: 2 of 3 prior buys achieved positive 90-day returns, with a 66.67% 90-day win rate at this specific ticker. However, the company remains unprofitable, posting net income of $-8.3M in the most recent quarter despite annual revenue growth of +8.4%. The current price of $46.25 sits 7.3% below the 52-week high, and the stock has gained 11.7% over the past 30 days, presenting a backdrop where execution and path to profitability become critical indicators of whether this buy thesis holds.

EVP Baur buys 5,310 DBD shares at $41.42; stock down -18.8% from 52-week high, company unprofitable

Baur Frank Tobias, EVP of Operational Excellence, purchased 5,310 shares at $41.42 on 2024-11-12, increasing his holdings by 21.9% to 29,572 shares. The transaction occurs as Diebold Nixdorf trades -18.8% from its 52-week high and faces fundamental headwinds: revenue declined -11.4% year-over-year, the company posted a net loss of $-22,400,000.00 in the latest quarter, and full-year net income was negative. A cluster pattern is present, with 2 other insiders also buying within the past 14 days. Notably, Baur's prior buy at this ticker on 2024-05-07 returned -9.5% over 90 days, and his cross-ticker track record shows a 0.00% win rate on 90-day outcomes across 2 prior buys. The purchase reflects accumulation amid depressed valuation but occurs in a context of operational challenges and prior unsuccessful timing patterns by this insider at this ticker.

DBD EVP Baur purchases 1,150 shares at $40.58 amid -11.4% annual revenue decline and full-year losses

Frank Tobias Baur, EVP of Operational Excellence at Diebold Nixdorf, purchased 1,150 shares for $46,669.53 on 2024-08-27 at $40.58, increasing his holdings by 5.0% to 24,262 shares. The transaction occurs in the context of material operational headwinds: the company reported full-year net losses, annual revenue contracted 11.4% year-over-year, and the current stock price of $40.91 sits 8.3% below the 52-week high of $44.60 while down 6.3% over the prior 30 days. Baur's cross-ticker trade history shows 1 prior buy with a 0.00% 90-day win rate, and his same-ticker history at DBD (a prior May 2024 purchase) also yielded a negative 90-day return of -9.5%, indicating a pattern of entries that have not generated positive returns on that horizon. The modest size of this purchase relative to his existing position and the broader context of company financial pressure suggest this transaction warrants deeper examination of timing and motivation.